Serum Proteomic Biomarker Discovery Reflective of Stage and Obesity in Breast Cancer Patients

被引:45
作者
Schaub, Nicholas P.
Jones, Kimberly J.
Nyalwidhe, Julius O.
Cazares, Lisa H.
Karbassi, Izabela D.
Semmes, O. John
Feliberti, Eric C.
Perry, Roger R.
Drake, Richard R. [1 ]
机构
[1] Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Ctr Biomed Proteom, Norfolk, VA 23507 USA
关键词
TUMOR-MARKERS; PROTEIN; INHIBITOR; PLASMA; IDENTIFICATION; CHEMOTHERAPY; NEOADJUVANT; VALIDATION; SURFACE; HEAD;
D O I
10.1016/j.jamcollsurg.2008.12.024
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Currently no standardized blood test exists for breast cancer screening or staging purposes. The goals of this Study were to use proteomic mass spectrometry approaches for profiling, fractionation, and identification of serum proteins from breast cancer patients for discovery of new biomarkers of stage and nodal status. STUDY DESIGN: Samples from 150 patients were collected preoperatively for patients undergoing breast biopsy. Serum was processed using weak cation exchange (WCX) fractionation and analyzed with matrix-assisted laser desorption ionization time of flight mass spectrometry. Spectra were processed and group profiles, peak statistics, and cross-validation scores were determined using a k-nearest neighbor genetic algorithm. Pools of subgroups based on stage, race, and obesity were processed with WCX fractionation followed by trypsin digestion. Differentially expressed proteins and peptides were identified by tandem mass spectrometry. RESULTS: Matrix-assisted laser desorption ionization time of flight proteomic profiling using WCX capture of serum proteins resulted in correct cancer stage classifications ranging from 72% to 84%. Nodal status was classified correctly with 88% cross-validation scores. Levels of endogenous low mass peptide fragments derived from kininogen, fibrinogen, plasminogen, and inter-alpha-trypsin inhibitor heavy chain 4 protein were increased in cancer stage III and stage IV samples. Adding trypsin digestions with WCX capture indicated increased levels of alpha-2-HS-glycoprotein, prothrombin, and Serum amyloid A in stage IV samples. Obesity, but not race, was a factor in the relative levels of detected proteins/peptides. CONCLUSIONS: WCX fractionation alone or with trypsin digestion of scrum suggest it can be possible to use a panel of proteins to predict breast cancer stage and nodal status. Additional study is required on the role of inflammatory molecules in breast cancer development. (J Am Coll Surg 2009;208: 970-980. (C) 2009 by the American College of Surgeons)
引用
收藏
页码:970 / 978
页数:9
相关论文
共 38 条
  • [1] Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
    Al Murri, AM
    Bartlett, JMS
    Canney, PA
    Doughty, JC
    Wilson, C
    McMillan, DC
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (02) : 227 - 230
  • [2] The benefits and limitations of sentinel lymph node biopsy
    Amersi F.
    Hansen N.M.
    [J]. Current Treatment Options in Oncology, 2006, 7 (2) : 141 - 151
  • [3] Inflammation-induced systemic proteolysis of inter-α-inhibitor in plasma from patients with sepsis
    Balduyck, M
    Albani, D
    Jourdain, M
    Mizon, C
    Tournoys, A
    Drobecq, H
    Fourrier, F
    Mizon, J
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2000, 135 (02): : 188 - 198
  • [4] Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer
    Becker, S
    Cazares, LH
    Watson, P
    Lynch, H
    Semmes, OJ
    Drake, RR
    Laronga, C
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (10) : 907 - 914
  • [5] Chatterjee Sabarni K, 2005, Future Oncol, V1, P37, DOI 10.1517/14796694.1.1.37
  • [6] Racial and ethnic differences in breast cancer survival - How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics?
    Curtis, Elana
    Quale, Chris
    Haggstrorn, David
    Smith-Bindman, Rebecca
    [J]. CANCER, 2008, 112 (01) : 171 - 180
  • [7] MALDI-TOF serum protein profiling for the detection of breast cancer
    de Noo, Mirre E.
    Deelder, Andre
    van der Werff, Martijn
    Ozalp, Aliye
    Mertens, Bart
    Tollenaar, Rob
    [J]. ONKOLOGIE, 2006, 29 (11): : 501 - 506
  • [8] Serum tumor markers in breast cancer: Are they of clinical value?
    Duffy, MJ
    [J]. CLINICAL CHEMISTRY, 2006, 52 (03) : 345 - 351
  • [9] Identification and confirmation of increased fibrinopeptide A serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry
    Ebert, Matthias P. A.
    Niemeyer, Dagmar
    Deininger, Soren O.
    Wex, Thomas
    Knippig, Claudia
    Hoffmann, Juliane
    Sauer, Jorg
    Albrecht, Wolfgang
    Malfertheiner, Peter
    Rocken, Christoph
    [J]. JOURNAL OF PROTEOME RESEARCH, 2006, 5 (09) : 2152 - 2158
  • [10] Fenton Joshua J, 2005, J Natl Cancer Inst Monogr, P67, DOI 10.1093/jncimonographs/lgi040